Supreme Court rejects limits on abortion pill mifepristone

[Pelican Press 0]

Supreme Court rejects limits on ********* pill mifepristone

The US Supreme Court has rejected an effort to sharply restrict access to the ********* pill mifepristone.

The justices decided the plaintiffs, a group of anti-********* doctors and activists, did not have a legal right to sue.

The decision, coming two years after the court rescinded the nationwide guarantee to an *********, is a major win for pro-choice activists.

Mifepristone is one of two drugs used in a medication *********, now the most common method of terminating pregnancies in the US.

The plaintiffs, known as the Alliance for Hippocratic Medicine, had argued that federal approval for the commonly used ***** should be withdrawn.

The court struck down the nationwide guarantee, known as Roe v Wade, in 2022. Since then, 21 states have moved to restrict ********* earlier in pregnancy than the standard it set. Seventeen of those have barred the procedure at six weeks or earlier.

Medication ********* – using pills sent by mail – has quickly become an effective workaround to those bans.

The two-***** regimen was approved for use up to 10 weeks of pregnancy by the Food and ***** Administration (FDA) in 2000. A patient is first given mifepristone to induce an ********* and then misoprostol to empty the *******.

Since 2016, the FDA has eased access to the ***** and has allowed doctors to hold virtual appointments with patients and for prescriptions to be sent by mail.

Throughout two decades of use, the FDA, the ********* College of Obstetrics and Gynaecologists (ACOG) and other mainstream medical organisations have maintained that both mifepristone and misoprostol are safe for use.

US studies say medication ********* is about 95% effective in ending pregnancy and requires further medical follow-up less than 1% of the time.

This is the hidden content, please

• Sign In
• or
• Sign Up

#Supreme #Court #rejects #limits #********* #pill #mifepristone

This is the hidden content, please

• Sign In
• or
• Sign Up